Sunitinib

Generic Name: Sunitinib

Brand Names: Sutent, Sunitinib Accord

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₇FN_₄O_₂

CAS Number: 557795-19-4

Unique Ingredient Identifier: V99T50803M

Background: Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.

Indication: Sunitinib is indicated for the following conditions:

Associated Conditions: Gastrointestinal Stromal Tumor (GIST), Renal Cell Carcinoma (RCC), Renal Cell Carcinoma Recurrent, Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin, Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin

Associated Therapies: -

Clinical Trials

Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma

Phase 1

Completed

Conditions: Metastatic Melanoma

Interventions: Drug: sunitinib malate
Drug: temozolomide

First Posted Date: 2009-11-01

Last Posted Date: 2020-08-03

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 16

Registration Number: NCT01005472

Locations: 🇺🇸
University of California Los Angeles (UCLA), Los Angeles, California, United States

A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma

Phase 2

Terminated

Conditions: Solid Tumor

Interventions: Drug: Sunitinib
Drug: CVX-060 + sunitinib

First Posted Date: 2009-09-23

Last Posted Date: 2015-11-20

Lead Sponsor: Pfizer

Target Recruit Count: 34

Registration Number: NCT00982657

Locations: 🇺🇸
Premiere Oncology, A Medical Corporation, Santa Monica, California, United States
🇺🇸
Premiere Oncology of Arizona, Scottsdale, Arizona, United States
🇺🇸
Boston Baskin Cancer Foundation, Memphis, Tennessee, United States

and more 1 locations

Stereotactic Radiosurgery With Sunitinib for Brain Metastases

Phase 1

Completed

Conditions: Brain Metastases

Interventions: Drug: Sunitinib

First Posted Date: 2009-09-22

Last Posted Date: 2022-10-07

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 22

Registration Number: NCT00981890

Locations: 🇨🇦
University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada

Evaluation of the Cost and Effectiveness Sunitinib Compared to Interferon-Alfa in Finland

Completed

Conditions: Neoplasms
Renal Cell Carcinoma

Interventions: Drug: sunitinib

First Posted Date: 2009-09-21

Last Posted Date: 2014-02-06

Lead Sponsor: Pirkko-Liisa Kellokumpu-Lehtinen

Target Recruit Count: 80

Registration Number: NCT00980213

Locations: 🇫🇮
Oulu Univeristy Hospital, Oulu, Finland
🇫🇮
Vaasa Central Hosptital, Vaasa, Finland
🇫🇮
Kuopio University Hospital, Kuopio, Finland

and more 2 locations

Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib

Phase 2

Completed

Conditions: Non-clear Cell Renal Cell Cancer

Interventions: Drug: Temsirolimus
Drug: Sunitinib

First Posted Date: 2009-09-18

Last Posted Date: 2012-07-10

Lead Sponsor: Central European Society for Anticancer Drug Research

Target Recruit Count: 22

Registration Number: NCT00979966

Locations: 🇩🇪
Vivantes Klinikum am Urban, Berlin, Germany
🇩🇪
Charité - Campus Virchow Klinikum, Berlin, Germany
🇩🇪
Charité - Mitte, Berlin, Germany

and more 11 locations

Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Clear Cell Adenocarcinoma
Recurrent Ovarian Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Sunitinib Malate

First Posted Date: 2009-09-18

Last Posted Date: 2020-02-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00979992

Locations: 🇺🇸
Los Angeles County-USC Medical Center, Los Angeles, California, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
🇺🇸
MetroHealth Medical Center, Cleveland, Ohio, United States

and more 94 locations

Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma

Phase 1

Terminated

Conditions: Renal Cell Carcinoma

Interventions: Drug: Lenalidomide
Drug: Sunitinib

First Posted Date: 2009-09-11

Last Posted Date: 2019-11-25

Lead Sponsor: Celgene

Target Recruit Count: 16

Registration Number: NCT00975806

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Cleveland Clinic Main Campus, Cleveland, Ohio, United States
🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States